You say of JP: "I don't think he could tell a fib if he tried and his genuineness is so compelling"
You then go on to contradict that statement: "the feeling I get is that they are under pressure doing all these trials (despite him saying they could do Phase 3 trials - I don't think it is realistic"
JP was very clear on why they are cancelling the current PWS trial. He was also clear that they wanted to run it again with more favourable protocols.
He was also crystal clear that Neuren could afford to run 2 Ph3 trials.
And as for the pressure they are under, "doing all these trials", they're literally working tirelessly with the aim of doing a whole lot more trials.
I take JP at face value.
Like you, I think JP mentioning Reata was an eye opener, and I do think, if and when a TO comes, this will be the benchmark. But, in the Reata context, JP mentioned that Reata's value was for an FDA approved drug for 1 indication.
So my takeaway is that I agree with Nashezz that a TO this year is not a certainty. FWIW, Goldenchook, on the Neuren Media and Analysts thread, posted what I think was the most thoughtful post on here in ages.
NEU Price at posting:
$23.97 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)